Premium
Oral iron supplementation in preterm infants treated with erythropoietin
Author(s) -
Fujiu Toru,
Maruyama Kenichi,
Koizumi Takenobu
Publication year - 2004
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/j.1442-200x.2004.01979.x
Subject(s) - medicine , erythropoietin , iron supplementation , pediatrics , anemia , intensive care medicine , iron deficiency
Background: It is not known whether a moderate dose of oral iron supplementation would further enhance erythropoiesis in recombinant human erythropoietin (EPO)‐treated very low‐birthweight (VLBW) infants.Methods: In total, 24 preterm infants with birthweights 750–1499 g were enrolled at the age of 14–28 days to receive 400 IU/kg per week EPO subcutaneously for 8 weeks. The infants were randomly allocated either to receive oral iron supplementation 4 mg/kg per day or to serve as controls.Results: Hemoglobin and the absolute reticulocyte count in the iron supplementation and the control groups remained identical throughout the study period, whereas serum ferritin was significantly lower in the control group at study exit and follow up. Rates of treatment success (no need for transfusion and hemoglobin never below 8 g/dL) also did not differ between the groups.Conclusions: In this study we did not find a clear advantage in a moderate dose of oral iron supplementation on erythropoiesis in EPO‐treated VLBW infants. Whether a higher dose would lead to enhanced erythropoiesis remains to be answered.